Immunotherapy Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Immunotherapy Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Multiple Sclerosis
Investigators at University of Basel have published new data on multiple sclerosis
November 26th, 2008
According to recent research from Basel, Switzerland, "The oral immunomodulator FTY720 has shown efficacy in patients with relapsing multiple sclerosis (MS). FTY720 functionally antagonizes sphingosine 1-phosphate receptor-1 (S1P1) on T cells and consequently inhibits S1P/S1P1-dependent lymphocyte egress from secondary lymphoid organs." "Little is known about the phenotype and function of T cells remaining in peripheral blood during long-term FTY720 treatment. T cells from FTY720-treated, interferon-beta (IFN beta)-treated and untreated patients with MS, and healthy donors (HD) were analyzed with respect to T cell subpopulation composition, proliferation, and cytokine...
Source: Immunotherapy Weekly (2008-11-26)
|
